Riskpilot← Back to searchSign inGet full access2San ApS
APSActiveCVR 41763965Jydekrogen 18Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20205 employees
Revenue 2024
DKK 565K
-196% vs 2023
EBITDA margin
-689.6%
+5% vs 2023
Equity ratio
83.1%
Financial strength
Net profit 2024
DKK -1,7M
+95% vs 2023
| Revenue | DKK 565K | -196% |
| EBITDA | DKK -3,9M | +5% |
| Net profit | DKK -1,7M | +95% |
| Total assets | DKK 149,5M | -4% |
| Equity | DKK 124,2M | -1% |
| Employees | 5 | — |
Legal name
2San ApS
CVR number
41763965
Legal form
Anpartsselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
10. oktober 2020
Share capital
DKK 64.100
Employees
5 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af 2 direktører eller af den samlede direktion.
Company purpose
Selskabets formål er at udøve virksomhed med handel og service, herunder distribution og salg af hygiejne produkter, samt aktiviteter i tilknytning hertil.
Address
Jydekrogen 18
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 63.455 | 637.326 | -589 | 565 |
| Staff expenses | -1.215 | -4.923 | -3.516 | -4.460 |
| EBITDA | 62.241 | 632.403 | -4.104 | -3.895 |
| Depreciation & amort. | -2 | -9 | -20 | -14 |
| EBIT | 62.239 | 632.394 | -4.124 | -3.909 |
| Net financials | -616 | -40.235 | -26.648 | 2.065 |
| Profit before tax | 61.623 | 592.159 | -30.772 | -1.690 |
| Tax | 13.707 | 131.513 | -8 | -0 |
| Net profit | 47.916 | 460.646 | -30.765 | -1.690 |
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 88.373 | 521.675 | 155.024 | 149.462 |
| Equity | 47.956 | 156.689 | 125.924 | 124.234 |
| Long-term debt | 10 | 8 | 0 | 0 |
| Short-term debt | 40.417 | 364.978 | 29.100 | 25.228 |
| Total debt | 40.417 | 364.978 | 29.100 | 25.228 |
EBITDA margin
-689.6%
This company
15.8%
Market median
-4465% vs market
20212024
Equity ratio
83.1%
This company
38.2%
Market median
+118% vs market
20212024
Return on equity
-1.4%
This company
18.4%
Market median
-108% vs market
20212024
Net profit margin
-299.2%
This company
8.1%
Market median
-3794% vs market
20212024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212024
Debt / equity
0.20×
This company
0.62×
Market median
+68% vs market
20212024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2020-10-10 – 2021-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
GC Management | Management | 2020 | — | — |
DC Management | Management | 2020 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100.0% | 100.0% | 2026 | |
| Individual | 25.0% | 25.0% | 2020 | |
| Individual | 10.0% | 10.0% | 2020 | |
2San ApS | Company | 15.0% | 15.0% | 2022 |
| Individual | 100.0% | 100.0% | 2025 | |
| Individual | 10.0% | 10.0% | 2020 | |
| Individual | 10.0% | 10.0% | 2020 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of 2San ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Greg Calder | Management | 0 companies |
| Daniel Calder | Management | 0 companies |